Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis

Nephron - Clinical Practice

Volumn 108, Issue 4, 2008, Pages

  Takei, Takashi ^a   Otsubo, Shigeru ^a   Uchida, Keiko ^a   Matsugami, Keiko ^b   Mimuro, Tomoko ^b   Kabaya, Takashi ^b   Akiba, Takashi ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Minami Senju Hospital   (Japan)

Author keywords

C reactive protein; Cholesterol; Haemodialysis; Phosphate binder; Sevelamer hydrochloride; Vascular calcification

Indexed keywords

CALCIUM; CALCIUM CARBONATE; LIPID; PARATHYROID HORMONE; PHOSPHORUS; SEVELAMER;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; LIPID BLOOD LEVEL; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANALYSIS OF VARIANCE; AORTA, ABDOMINAL; AORTIC DISEASES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCINOSIS; CALCIUM; CALCIUM CARBONATE; CHELATING AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; POLYAMINES; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 43949099664     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000127361     Document Type: Article

References (31)

1. Davies MR, Hruska KA: Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 2001;60:472-479.
2. Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Anderson JT, Weil R III: Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 1979;66:790-796.
3. Ansari A, Kaupke CJ, Vaziri ND, Miller R, Barbari A: Cardiac pathology in patients with end-stage renal disease maintained on hemodialysis. Int J Artif Organs 1993;16:31-36.
4. O'Rourke M: Mechanical principles in arterial disease. Hypertension 1995;26:2-9.
5. Block GA: Prevalence and clinical consequences of elevated Ca ! P product in hemodialysis patients. Clin Nephrol 2000;54:318-324.
6. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-617.
7. Goodman WG, Goldin J, Kuizon BD, Yoo C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.
8. Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H: Vascular calcification and inorganic phosphate. Am J Kidney Dis 2001; 38(4 suppl 1):S34-S37.
9. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701.
10. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E: Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997;29:66-71.
11. Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, Weinberg M, Wombolt D, Burke SK: Effect of RenaGel, a non-absorbed, calcium- and aluminiumfree phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998;13:2303-2310.
12. Wilkes BM, Reiner D, Kern M, Burke S: Simultaneous lowering of serum phosphate and LDL cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol 1998;50:381-386.
13. Bleyer AJ, Burke SK, Dillon MA, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999;33:694-701.
14. Chertow GM, Burke SK, Dillon MA, Slatopolsky E: Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 1999;14:2907-2914.
15. Slatopolsky EA, Burke SK, Dillon MA: Rena-Gel, a nonabsorbed calcium- and aluminium-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999;55:299-307.
16. Chertow GM, Dillon MA, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E: A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium: strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999;51:18-26.
17. Kabaya T, Nitta K, Kimura H, Kawashima A, Mimuro T, Narusawa K, Nihei H: An increased serum level of parathyroid hormone is a risk factor for aortosclerosis in hemodialysis patients. Nephron 2000;86:213-214.
18. Nitta K, Akiba T, Kawashima A, Kimata N, Miwa N, Uchida K, Honda K, Takei T, Otsubo S, Yumura W, Kabaya T, Nihei H: Serum levels of macrophage colony-stimulating factor and aortic calcification in hemodialysis patients. Am J Nephrol 2001;21:465-470.
19. Tomson C: Vascular calcification in chronic renal failure. Nephron Clin Pract 2003;93:c124-c130.
20. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.
21. Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD: The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003;23:307-314.
22. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996;27:394-401.
23. Kimura K, Saika Y, Otani H, Fujii R, Mune M, Yukawa S: Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int 1999;56(suppl 71):S283-S241.
24. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival of patients in end-stage renal failure. Circulation 2001;103:987-992.
25. Schwartz U, Buzello M, Ritz E, Stein G: Morphology of coronary atherosclerosis lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000;15:218-223.
26. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-1021.
27. Zimmerman J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648-658.
28. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, Nihei H: The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003;42:303-309.
29. Tamashiro M, Iseki K, Sunagawa O, Inoue T, Higa S, Afuso H, Fukiyama K: Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis 2001;38:64-69.
30. Oprisiu R, Bunea D, Tarek S, Hedi B, Fournier A: Progression of vascular calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis 2001;39:209.
31. Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Knez A, Menendez T, Maeffert R, Kusus M, Regenfus M, Bickel A, Haberl R, Steinbeck G, Moshage W, Daniel WG: Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 2002;106:1077-1082.